Professor Raphael Mechoulam
born: 1930 (Sofia, Bulgaria)
for Medicinal Chemistry
and Natural Products
Faculty of Medicine, Hebrew University of Jerusalem
Ein Kerem, Jerusalem 91010
Mechoulam is with the Department of Medicinal Chemistry and
Natural Products at the Faculty of Medicine. He is former Rector of
the University and is a member of the Israel Academy of Sciences. His
research interests are in the field of the chemistry and biological
activity of natural products and medicinal agents. His main contributions
are in the field of the constituents of cannabis and the endogenous
cannabinoids found in the brain and the periphery. He has published
extensively on their pharmacological activities.
of recent research publications:
Y. Gaoni and R. Mechoulam.
Isolation, structure and partial synthesis of an active constituent of hashish.
J. Amer. Chem. Soc., 86, 1646 (1964).
R. Mechoulam, A. Shani,
H. Edery and Y. Grunfeld. The chemical basis of hashish activity. Science,
169, 611-612 (1970).
J.J. Feigenbaum F. Bergmann,
S.A. Richmond, R. Mechoulam, V. Nadler, Y. Kloog and M. Sokolovsky. A non-psychotropic
cannabinoid acts as a functional N-methyl-D-asparate (NMDA) receptor blocker.
Proc. Nat. Acad. Sci. 86, 9584-9587 (1989).
R. Seltzer, Z. Zeltser,
A. Eisen, J.J. Feigenbaum and R. Mechoulam. Suppression of neuropathic pain
behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-
blocking properties. Pain 47, 95-103 (1991).
W.A. Devane, L. Hanus,
A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum,
A. Etinger and R. Mechoulam. Isolation and structure of a brain constituent
that binds to the cannabinoid receptor. Science 258, 1946-1949 (1992).
R. Mechoulam, S. Ben-Shabat,
L. Hanus, M. Ligumsky, N.E. Kaminski, A.R. Schatz, A. Gopher, S. Almog,
B.R. Martin, D.R. Compton, R.G. Pertwee, G. Griffin, M. Bayewitch, J. Barg
and Z. Vogel. Identification of an endogenous 2-monoglyceride, present in
canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50,
L. Hanus, A. Breuer,
S. Tchilibon, S. Shiloah, D. Goldenberg, M. Horowitz, R.G.Pertwee , R.A.Ross,
R. Mechoulam and E. Fride. HU-308: A specific agonist for CB2, a peripheral
cannabinoid receptor. Proc. Natl. Acad. Sci. (US), 96, 14228-14233 (1999).
A.M. Malfait, R. Gallily,
P.F. Sumariwalla, A.S. Malik, E. Andreakos, R. Mechoulam, M. Feldmann. The
non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritic
therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci
(USA) 97, 9561-9566 (2000).
L. Hanus, S. Abu-Lafi,
E. Fride, A. Breuer, Z. Vogel, D.E. Shalev, I. Kustanovich and R. Mechoulam.
2-Arachidonyl glycerol ether, endogenous agonist of the cannabinoid CB1
receptor. Proceed. Natl. Acad. Sci. (USA) 98, 3662-3665 (2001).
D. Panikashvili, C. Simeonidou,
S. Ben-Shabat, L. Hanus, A. Breuer, R. Mechoulam and E. Shohami. An endogenous
cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527-531
^ Top of page